Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]
News [5292]
Articles [130]
Editorials [4]
Conferences [158]
elearning [13]
Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma
Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium
Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )
5 Jun 2015
ASCO 2015: Latest developments in multiple myeloma
Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos
ASCO 2015: Latest developments in multiple myeloma ( Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos )
1 Jun 2015
Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma
Dr James Larkin - Royal Marsden Hospital, London, UK
Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma ( Dr James Larkin - Royal Marsden Hospital, London, UK )
1 Jun 2015
Non-randomised clinical trial aims to describe the safety and efficacy of...
Dr Richard Schilsky - University of Chicago, Chicago, USA
Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs ( Dr Richard Schilsky - University of Chicago, Chicago, USA )
1 Jun 2015
Developments in clinical trials and health information technology that will...
Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA
Developments in clinical trials and health information technology that will improve targeted therapies for patients ( Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA )
1 Jun 2015
Obinutuzumab doubles remission duration in patients with relapsed, indolent non...
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )
31 May 2015
New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin...
Dr Merry-Jennifer Markham - University of Florida, Florida, USA
New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis ( Dr Merry-Jennifer Markham - University of Florida, Florida, USA )
30 May 2015
New ibrutinib combination regimen shows substantial benefits in relapsed...
Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA
New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia ( Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )
30 May 2015
Obinutuzumab doubles remission duration in patients with relapsed, indolent non...
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )
30 May 2015
Pembrolizumab for head and neck cancer
Dr Tanguy Seiwert - University of Chicago, Chicago, USA
Pembrolizumab for head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )
29 May 2015
Pembrolizumab shows promising activity against head and neck cancer
Dr Tanguy Seiwert - University of Chicago, Chicago, USA
Pembrolizumab shows promising activity against head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )
29 May 2015
Prostate cancer and pharmacokinetics: Expert discussion
Prof Axel S. Merseburger and Prof Romano Danesi
Prostate cancer and pharmacokinetics: Expert discussion ( Prof Axel S. Merseburger and Prof Romano Danesi )
26 May 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation